Phase III randomized trial in patients with poor-prognosis metastatic germ cell tumors Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • The routine inclusion of HDCT in first-line treatment for GCT patients with metastases and a poor predicted outcome to chemotherapy did not improve treatment outcome. Frequent serum marker determinations to estimate marker decline during the first two cycles of BEP chemotherapy provide a clinically useful estimate of outcome.

publication date

  • May 2007

Research

keywords

  • Academic Article

Additional Document Info

start page

  • 247

end page

  • 56

volume

  • 6

number

  • 5